BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

968 related articles for article (PubMed ID: 16916471)

  • 1. Activity and expression of urokinase-type plasminogen activator and matrix metalloproteinases in human colorectal cancer.
    Kim TD; Song KS; Li G; Choi H; Park HD; Lim K; Hwang BD; Yoon WH
    BMC Cancer; 2006 Aug; 6():211. PubMed ID: 16916471
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Increased TIMP/MMP ratio in varicose veins: a possible explanation for extracellular matrix accumulation.
    Badier-Commander C; Verbeuren T; Lebard C; Michel JB; Jacob MP
    J Pathol; 2000 Sep; 192(1):105-12. PubMed ID: 10951407
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Short chain fatty acids inhibit human (SW1116) colon cancer cell invasion by reducing urokinase plasminogen activator activity and stimulating TIMP-1 and TIMP-2 activities, rather than via MMP modulation.
    Emenaker NJ; Basson MD
    J Surg Res; 1998 Apr; 76(1):41-6. PubMed ID: 9695737
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expression of serine proteases and metalloproteinases in human pituitary adenomas and anterior pituitary lobe tissue.
    Knappe UJ; Hagel C; Lisboa BW; Wilczak W; Lüdecke DK; Saeger W
    Acta Neuropathol; 2003 Nov; 106(5):471-8. PubMed ID: 12904990
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Increased expression of matrix metalloproteinases (MMP)-2, MMP-9, and the urokinase-type plasminogen activator is associated with progression from benign to advanced ovarian cancer.
    Schmalfeldt B; Prechtel D; Härting K; Späthe K; Rutke S; Konik E; Fridman R; Berger U; Schmitt M; Kuhn W; Lengyel E
    Clin Cancer Res; 2001 Aug; 7(8):2396-404. PubMed ID: 11489818
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Matrix metalloproteinases, their tissue inhibitors and colorectal cancer staging.
    Baker EA; Bergin FG; Leaper DJ
    Br J Surg; 2000 Sep; 87(9):1215-21. PubMed ID: 10971431
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Melatonin inhibits postischemic matrix metalloproteinase-9 (MMP-9) activation via dual modulation of plasminogen/plasmin system and endogenous MMP inhibitor in mice subjected to transient focal cerebral ischemia.
    Tai SH; Chen HY; Lee EJ; Chen TY; Lin HW; Hung YC; Huang SY; Chen YH; Lee WT; Wu TS
    J Pineal Res; 2010 Nov; 49(4):332-41. PubMed ID: 20663046
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The p75(NTR) metastasis suppressor inhibits urokinase plasminogen activator, matrix metalloproteinase-2 and matrix metalloproteinase-9 in PC-3 prostate cancer cells.
    Nalbandian A; Djakiew D
    Clin Exp Metastasis; 2006; 23(2):107-16. PubMed ID: 16912916
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Matrix metalloproteinase-9,-3 and tissue inhibitor of matrix metalloproteinase-1 in colorectal cancer: relationship to clinicopathological variables.
    Işlekel H; Oktay G; Terzi C; Canda AE; Füzün M; Küpelioğlu A
    Cell Biochem Funct; 2007; 25(4):433-41. PubMed ID: 16615041
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Expression of various matrix proteases and Ets family transcriptional factors in ovarian cancer cell lines: correlation to invasive potential.
    Nishikawa A; Iwasaki M; Akutagawa N; Manase K; Yamashita S; Endo T; Kudo R
    Gynecol Oncol; 2000 Nov; 79(2):256-63. PubMed ID: 11063654
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expression and activation of proteases in co-cultures.
    Paduch R; Kandefer-Szerszeń M
    Exp Toxicol Pathol; 2011 Jan; 63(1-2):79-87. PubMed ID: 19836935
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expression of matrix metalloproteinases-1, -2, and -9; tissue inhibitors of matrix metalloproteinases-1 and -2; cathepsin B; urokinase plasminogen activator; and plasminogen activator inhibitor, type I in skull base chordoma.
    Naka T; Kuester D; Boltze C; Schulz TO; Samii A; Herold C; Ostertag H; Roessner A
    Hum Pathol; 2008 Feb; 39(2):217-23. PubMed ID: 17949787
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Vein wall remodeling after deep vein thrombosis involves matrix metalloproteinases and late fibrosis in a mouse model.
    Deatrick KB; Eliason JL; Lynch EM; Moore AJ; Dewyer NA; Varma MR; Pearce CG; Upchurch GR; Wakefield TW; Henke PK
    J Vasc Surg; 2005 Jul; 42(1):140-8. PubMed ID: 16012463
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Urokinase-type plasminogen activator, receptor, and inhibitor correlating with gelatinase-B (MMP-9) contribute to inflammation in gouty arthritis of the knee.
    Chu SC; Yang SF; Lue KH; Hsieh YS; Hsiao TY; Lu KH
    J Rheumatol; 2006 Feb; 33(2):311-7. PubMed ID: 16465663
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The urokinase-system in tumor tissue stroma of the breast and breast cancer cell invasion.
    Hildenbrand R; Schaaf A
    Int J Oncol; 2009 Jan; 34(1):15-23. PubMed ID: 19082473
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Limited value of preoperative serum analyses of matrix metalloproteinases (MMP-2, MMP-9) and tissue inhibitors of matrix metalloproteinases (TIMP-1, TIMP-2) in colorectal cancer.
    Oberg A; Höyhtyä M; Tavelin B; Stenling R; Lindmark G
    Anticancer Res; 2000; 20(2B):1085-91. PubMed ID: 10810401
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expressions of urokinase-type plasminogen activator, its receptor and plasminogen activator inhibitor-1 in gastric cancer cells and effects of Helicobacter pylori.
    Iwamoto J; Mizokami Y; Takahashi K; Nakajima K; Ohtsubo T; Miura S; Narasaka T; Takeyama H; Omata T; Shimokobe K; Ito M; Takehara H; Matsuoka T
    Scand J Gastroenterol; 2005 Jul; 40(7):783-93. PubMed ID: 16109653
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Brain-derived neurotrophic factor inducing angiogenesis through modulation of matrix-degrading proteases.
    Sun CY; Hu Y; Wang HF; He WJ; Wang YD; Wu T
    Chin Med J (Engl); 2006 Apr; 119(7):589-95. PubMed ID: 16620701
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Expression of matrix metalloproteinases and related tissue inhibitors in the cyst fluids of ovarian mucinous neoplasms.
    Furuya M; Ishikura H; Kawarada Y; Ogawa Y; Sakuragi N; Fujimoto S; Yoshiki T
    Gynecol Oncol; 2000 Aug; 78(2):106-12. PubMed ID: 10926788
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Urokinase plasminogen activator stimulates function of active forms of stromelysin and gelatinases (MMP-2 and MMP-9) in cirrhotic tissue.
    González-Cuevas J; Bueno-Topete M; Armendariz-Borunda J
    J Gastroenterol Hepatol; 2006 Oct; 21(10):1544-54. PubMed ID: 16928215
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 49.